Scientific Article
previous document  unige:29842  next document
add to browser collection

Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases

Thaci, Diamant
Patzold, S.
Kaufmann, Roland
Published in British Journal of Dermatology. 2005, vol. 152, no. 5, p. 1048-1050
Abstract Alefacept is a fully human fusion protein for use in adult patients with moderate to severe chronic plaque psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. We report the clinical course of two patients with hepatitis C virus (HCV) infection who have received alefacept for psoriasis. Consistent with its mechanism of action, administration of alefacept led to transient decreases in CD4+ and CD8+ T-cell counts. However, these reductions were not associated with an increase in HCV viral load or exacerbation of infection. Liver enzymes remained stable throughout the treatment and follow-up periods. Alefacept has a selective mechanism of action that specifically targets memory T cells and this selectivity may account for its safety and tolerability in patients with hepatitis.
Keywords AdultCD4 Lymphocyte CountCD8-Positive T-Lymphocytes/immunologyHepatitis C/*complications/immunology/virologyHumansImmunosuppressive Agents/*therapeutic useLymphocyte CountMaleMiddle AgedPsoriasis/complications/*drug therapy/immunologyRecombinant Fusion Proteins/*therapeutic useViral Load
PMID: 15888169
Full text
(ISO format)
THACI, Diamant et al. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. In: British Journal of Dermatology, 2005, vol. 152, n° 5, p. 1048-1050.

151 hits

0 download


Deposited on : 2013-09-20

Export document
Format :
Citation style :